Inhibition of allergic airways disease by immunomodulatory therapy with whole killed Streptococcus pneumoniae

Julie A. Preston; Ama Tawiah Essilfie; Jay C. Horvat; Margaret A. Wade; Kenneth W. Beagley; Peter G. Gibson; Paul S. Foster; Philip M. Hansbro

doi:10.1016/j.vaccine.2007.09.034

Inhibition of allergic airways disease by immunomodulatory therapy with whole killed Streptococcus pneumoniae

Julie A. Preston, Ama Tawiah Essilfie, Jay C. Horvat, Margaret A. Wade, Kenneth W. Beagley, Peter G. Gibson, Paul S. Foster, Philip M. Hansbro^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

72 Citations (Scopus)

Abstract

Asthma is a common inflammatory disease of the airways. Current therapies alleviate symptoms but do not treat the disease. We aim to develop effective immunomodulatory therapies (IMTs) for asthma that target the underlying causes of disease based on Streptococcus pneumoniae (Spn). The effect of Spn IMT on the development of asthma [allergic airways disease (AAD)] was determined in mice. Killed Spn was administered before, during or after ovalbumin sensitization, and the subsequent development of AAD was assessed. IMT attenuated T cell cytokine production, goblet cell hyperplasia, airways hyperresponsiveness (AHR), and eosinophil numbers in the blood, bronchoalveolar lavage fluid and peribronchial tissue. This indicates the potential of Spn as an IMT for asthma.

Original language	English
Pages (from-to)	8154-8162
Number of pages	9
Journal	Vaccine
Volume	25
Issue number	48
DOIs	https://doi.org/10.1016/j.vaccine.2007.09.034
Publication status	Published - 23 Nov 2007

Access to Document

10.1016/j.vaccine.2007.09.034

Cite this

@article{95d07a3153db40d4a7263f46d713a974,

title = "Inhibition of allergic airways disease by immunomodulatory therapy with whole killed Streptococcus pneumoniae",

abstract = "Asthma is a common inflammatory disease of the airways. Current therapies alleviate symptoms but do not treat the disease. We aim to develop effective immunomodulatory therapies (IMTs) for asthma that target the underlying causes of disease based on Streptococcus pneumoniae (Spn). The effect of Spn IMT on the development of asthma [allergic airways disease (AAD)] was determined in mice. Killed Spn was administered before, during or after ovalbumin sensitization, and the subsequent development of AAD was assessed. IMT attenuated T cell cytokine production, goblet cell hyperplasia, airways hyperresponsiveness (AHR), and eosinophil numbers in the blood, bronchoalveolar lavage fluid and peribronchial tissue. This indicates the potential of Spn as an IMT for asthma.",

keywords = "Asthma, Immunomodulation, Streptococcus pneumoniae",

author = "Preston, {Julie A.} and Essilfie, {Ama Tawiah} and Horvat, {Jay C.} and Wade, {Margaret A.} and Beagley, {Kenneth W.} and Gibson, {Peter G.} and Foster, {Paul S.} and Hansbro, {Philip M.}",

year = "2007",

month = nov,

day = "23",

doi = "10.1016/j.vaccine.2007.09.034",

language = "English",

volume = "25",

pages = "8154--8162",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier B.V.",

number = "48",

}

TY - JOUR

T1 - Inhibition of allergic airways disease by immunomodulatory therapy with whole killed Streptococcus pneumoniae

AU - Preston, Julie A.

AU - Essilfie, Ama Tawiah

AU - Horvat, Jay C.

AU - Wade, Margaret A.

AU - Beagley, Kenneth W.

AU - Gibson, Peter G.

AU - Foster, Paul S.

AU - Hansbro, Philip M.

PY - 2007/11/23

Y1 - 2007/11/23

N2 - Asthma is a common inflammatory disease of the airways. Current therapies alleviate symptoms but do not treat the disease. We aim to develop effective immunomodulatory therapies (IMTs) for asthma that target the underlying causes of disease based on Streptococcus pneumoniae (Spn). The effect of Spn IMT on the development of asthma [allergic airways disease (AAD)] was determined in mice. Killed Spn was administered before, during or after ovalbumin sensitization, and the subsequent development of AAD was assessed. IMT attenuated T cell cytokine production, goblet cell hyperplasia, airways hyperresponsiveness (AHR), and eosinophil numbers in the blood, bronchoalveolar lavage fluid and peribronchial tissue. This indicates the potential of Spn as an IMT for asthma.

AB - Asthma is a common inflammatory disease of the airways. Current therapies alleviate symptoms but do not treat the disease. We aim to develop effective immunomodulatory therapies (IMTs) for asthma that target the underlying causes of disease based on Streptococcus pneumoniae (Spn). The effect of Spn IMT on the development of asthma [allergic airways disease (AAD)] was determined in mice. Killed Spn was administered before, during or after ovalbumin sensitization, and the subsequent development of AAD was assessed. IMT attenuated T cell cytokine production, goblet cell hyperplasia, airways hyperresponsiveness (AHR), and eosinophil numbers in the blood, bronchoalveolar lavage fluid and peribronchial tissue. This indicates the potential of Spn as an IMT for asthma.

KW - Asthma

KW - Immunomodulation

KW - Streptococcus pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=35848933938&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2007.09.034

DO - 10.1016/j.vaccine.2007.09.034

M3 - Article

SN - 0264-410X

VL - 25

SP - 8154

EP - 8162

JO - Vaccine

JF - Vaccine

IS - 48

ER -

Inhibition of allergic airways disease by immunomodulatory therapy with whole killed Streptococcus pneumoniae

Abstract

Access to Document

Other files and links

Fingerprint

Cite this